ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency
March 19, 2024 08:07 ET
|
ClearPoint Neuro, Inc.
ClearPoint Neuro's partner's completed BLA Submission for Upstaza™ would be first disease-modifying treatment for AADC Deficiency in the US.
ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results
March 12, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
ClearPoint Neuro reports 32% growth in fourth quarter as compared to fourth quarter of 2022. Biologics revenue increased 49% YOY.
Journal of Neurosurgery Publication Demonstrates Distinct Advantages of ClearPoint Prism® Neuro Laser Therapy System
March 11, 2024 08:00 ET
|
ClearPoint Neuro, Inc.
ClearPoint Neuro announces peer-reviewed publication showing correlation of software lesion size to histopathology, only FDA-cleared laser with correlation
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024
March 01, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation...
ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock
February 29, 2024 08:00 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to...
ClearPoint Neuro Launches Proposed Public Offering of Common Stock
February 28, 2024 16:45 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to...
ClearPoint Neuro Announces FDA Clearance and First-in-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model
February 21, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
ClearPoint Neuro announces FDA Clearance and first-in-human cases using 2.2 Software with integrated Maestro Brain Modeling, and publication in NeuroImage
ClearPoint Neuro Announces Installation and First Procedure Using the ClearPoint Prism® Neuro Laser Therapy System and Navigation System at Kaleida Health in Buffalo
January 24, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
First successful procedure with ClearPoint Prism Neuro Laser Therapy System and Neuro Navigation System by Kaleida Health in Buffalo.
ClearPoint Neuro annoncerer første EU MDR certificeringssucces og godkendelse til at sende produkt til Europa
January 22, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Californien, Jan. 22, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) ("Virksomheden"), en global enhed, celle- og genterapi-virksomhed, der tilbyder præcis navigation...
ClearPoint Neuro Announces First EU MDR Certification Success and Approval to Ship Product to Europe
January 22, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
ClearPoint Neuro announces first EU MDR certification success and approval to ship product to Europe from its Carlsbad, California manufacturing facility.